Follow us...


Search News Archives

Special Offers and Promotions



News Channels

Lab News


View Channel

New Laboratory Products


View Channel

Microscopy | Image Analysis


View Channel

Separation Science


View Channel

Research & Case Studies


View Channel

Coronavirus (COVID-19)



View Channel

Brochures & Literature


View Channel



Conferences | Events

Test kit identifies genetic risk of thrombosis

Test kit identifies genetic risk of thrombosisAstra Biotech GmbH announces a new genetic test kit which identifies hereditary thrombophilia - a significant risk factor in the development of potentially life-threatening deep vein thrombosis and pulmonary embolism. In line with the company's aim of facilitating disease prevention and improving quality of life, the Astra Thrombosis kit detects three common mutations which disrupt the blood coagulation mechanism.

Test kit identifies genetic risk of thrombosisThe consequences of thrombosis can be severe - pulmonary embolism (PE), myocardial infarction, stroke and infertility - and thrombosis is one of the most widespread causes of morbidity and mortality in developed countries. Hereditary thrombophilia, the propensity to develop thrombosis, is an important factor influencing development of deep vein thrombosis (DVT) and PE. Additional risk factors include pregnancy, prolonged immobilization, surgical intervention, injury and smoking.

The Astra Thrombosis kit enables identification of hereditary thrombophilia and estimation of a patient's risk of developing DVT and PE. Following extraction of the patient's total DNA sample from blood tissue or epithelium, three single nucleotide polymorphisms in the F5, F2 and MTHFR genes can be simultaneously detected using the kit. The method is multiplex PCR with subsequent restriction and polyacrylamide or agarose gel electrophoresis. The diagnostic kit includes two PCR mixes, positive controls, DNA-polymerase, restriction enzyme and buffer.

Testing for hereditary thrombophilia is recommended in various circumstances, such as venous embolism occurring before the age of 50, repeatedly, or during pregnancy or the postnatal period, and for members of families with expressed hereditary thrombophilia.

For more information visit

If you have not logged into the website then please enter your details below.



Popular this Month...

Our Top 10 most popular articles this month


Today's Picks...




Looking for a Supplier?

Search by company or by product


Company Name:




Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.



Media Partner